Day One Biopharmaceuticals Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
21.45
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
Max
Pajamos | -1.6M -21M |
|---|---|
Pardavimai | 14M 54M |
Pelno marža | -39.611 |
Darbuotojai | 178 |
EBITDA | -7.7M -26M |
Rekomendacijos | Neutralu |
|---|---|
12 mėnesių prognozė | -3.62% downside |
Rinkos kapitalizacija | 1B 2.2B |
|---|---|
Ankstesnė atidarymo kaina | 21.45 |
Ankstesnė uždarymo kaina | 21.45 |
Naujienos nuotaikos
By Acuity
50%
50%
155 / 342 reitingas Healthcare
Day One Biopharmaceuticals Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
